Viatris Inc vs Western Union Co — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Western Union Co trades at $6.95 (market cap $2.18B). The key difference: Viatris Inc is far larger — about 8.8× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.43%). Which is the better fit depends on your goals.
| VTRS | WU | |
|---|---|---|
Market Cap | $19.09B | $2.18B |
Sector | Health | Technology |
52-Week High | $17.86 | $10.28 |
52-Week Low | $9.49 | $6.36 |
Enterprise Value | $31.21B | $2.09B |
Dividend Yield | 2.89% | 13.43% |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Western Union (WU) trades at $7.00, down 2.51% on the day, reflecting a bearish technical trend and mixed earnings performance with recent quarterly misses. Valuation metrics appear attractive with a P/E of 5.65 and P/S of 0.55, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company is pursuing a $200 million cost-saving plan by 2027 and expanding its retail footprint through partnerships like Total Wireless, while its pending acquisition of Intermex faces regulatory scrutiny.
The outlook is cautious due to declining revenue, integration risks from the Intermex deal, and a high dividend yield that some analysts view as unsustainable. Near-term catalysts include regulatory approvals for the acquisition and execution of cost-cutting initiatives, but competitive pressures and margin compression pose significant risks to shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →